Today Stories

Enhancing the research and production of drugs in Europe Major investment solidifies Germany’s and Europe’s position as a leading production hub for global medication supply Boehringer Ingelheim breaks ground to build a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. In the presence of German Chancellor Olaf Scholz and Rhineland-Palatinate Minister-President Malu Dreyer, the foundation stone for the major investment of 285 million EUR was laid today. Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultima…

National Biotechnology Company Adds New Location in Louisiana BATON ROUGE, La.--(BUSINESS WIRE)--ImmunoTek Bio Centers opens its 80th and newest ImmunoTek Plasma location in Baton Rouge on Tuesday, May 2, 2023. As the world's largest independent blood and plasma donation center operator, ImmunoTek invites the Baton Rouge community to visit the state-of-the-art facility to learn more about plasma donations and how they can positively impact others. By removing the red and white blood cells from the blood, what remains is the golden liquid called plasma. Blood-plasma helps create medicines and plasma-based therapies that treat patients with various diseases and disorders, including shock and burn patients, bleeding disorders, transplant patients, those suffering from autoimmune diseases, and…

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed Giovanni Caforio, MD, as CEO, Effective November 1, 2023 Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer, effective immediat…

Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared…

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhan…

Bern, Switzerland and Boston, U.S.A., 21 April, 2023 – RetinAI Medical AG (“RetinAI”), a leader in clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is excited to announce a new partnership with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery® platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, advanced form of age-related macular degeneration and a leading cause of complete loss of sight, estimated to affect around 5 million people worldwide1. The number of people affected by GA increases exponentially with age. As the population ages, the prevalence of the disease is expected to rise.1,2 T…

UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology CRO – has announced the next phase in its ongoing growth plan with the opening of a brand-new 2,819 sq ft laboratory and office suite at Alderley Park. The newly established suite will accommodate the activities of the Big Blue® transgenic rodent mutation workflow, increasing capacity in this in-demand mutagenesis toxicology test and growing the Gentronix footprint at Alderley Park by 30%. This continued growth follows a successful 2300 sq ft. expansion in 2021 to increase capacity of genetic, ocular, and skin toxicology testing in 2021. Gentronix completed the acquisition of the Big Blue® transgenic rodent mutation assays in June 2021 and have subsequently undertaken an extensive proficiency exercise…

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council In three years' time, Gilde Healthcare raised over €1.5 billion across three funds UTRECHT, Netherlands, April 19, 2023 /PRNewswire/ -- Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics. The fund is…

In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs INDIANAPOLIS, April 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7 billion and up to 700 new jobs. The company also today committed $15 million over five years to the Ivy Tech Foundation to fund up to 1,000 scholarships for individuals interested in pursuing careers in pharmaceutical manufacturing. Lilly's commitments within LEAP Innovation Park represent the largest manufacturing investment at a s…

Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 bil…

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportuni…

A pioneering biotech firm has secured £13.2 million to fund its mission to develop the world’s first treatment for a rare, incurable and deadly disease.   SynaptixBio, whose aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy, has successfully raised £11.05m in its latest funding round to add to the £2.125m of seed funding from the last two years. Both rounds have come exclusively from private investment.   The Oxfordshire-based research firm believes the investment will fund the rest of its research into a treatment and take it to human clinical trials next year.   First identified in 2015, TUBB4A-related leukodystrophy, which is believed to mainly affect babies and young children, is caused by a mutation in the TUBB4A gene. It disrupts the signals bet…

Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to receive 75 million US dollars in initial payments and up to 650 million dollars in future milestone payments per product arising from the collaboration, plus tiered royalties. Vancouver, BC, Canada and Bagsværd, Denmark, 12 April 2023 – Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will lever…

RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the list in 2021. “Our talented, diverse team is foundational to our ability to deliver on our purpose of saving and improving lives around the world,” said Steven C. Mizell, executive vice president and chief human resources officer, Merck. “We are honored by this significant recognition, which is reflective of our vibrant and inclusive culture, where employees feel seen, heard, valued and set up for continued success.” This year’s Best Companies to Work For list is based on the feedback of more than half a million U.S. employees, who responded to a nation…

Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics. Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement Conference at Queen’s to highlight Northern Ireland’s emerging global reputation in the translational oncology ecosystem. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University…

Today marks World Health Day, as well as the World Health Organization’s 75th birthday. This year’s theme is ‘Health For All’ – a theme envisioning that all people have good health for a fulfilling life in a peaceful, prosperous, and sustainable world. The right to health is a basic human right. Everyone must have access to the health services they need when and where they need them without financial hardship. Did you know: 30% of the global population is not able to access essential health services Almost two billion people face catastrophic or impoverishing health spending, with significant inequalities affecting those in the most vulnerable settings Between 2023-2030 there is a projected shortfall of 10 million health workers worldwide Find out more about World Health Day 2023, and th…

Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for Best Contract Research Organization (CRO). Presented at the 2023 World Vaccine Congress in Washington, D.C., the award recognizes the vaccine industry’s most outstanding efforts, accomplishments and positive contributions of companies and individuals. Syneos Health has an extensive range of industry-leading expertise in bacteriology, virology, mycology, and associated diseases and syndromes. In the past five years, the Company’s Catalyst Vaccine Network sites have conducted more than 700 vaccine stud…

RAHWAY, N.J.-–(3BL MEDIA)-– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year—from No. 67 overall in 2022 to No. 29 overall in 2023.    “At Merck, we are committed to operating responsibly and moving with urgency to deliver value for patients, society and all of our stakeholders,” said Carmen Villar, vice president of Social Business Innovation for Merck. “We are pleased to see the impact of our work being recognized, and we will continue to make strides toward building a healthier, safer and more sustainable world.” Earlier this year, Merck was also recognized as…

Partnership will distribute screening kits to communities at higher risk of colon cancer BURLINGTON, N.C., April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches will distribute over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond. Colorectal cancer, which is the third most deadly type of cancer in the U.S., has a disproportionate impact on the Black community, according to the American…

New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation DUBLIN and DENVER, April 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) today announced the launch of Mozarc Medical—an independent new company committed to reshaping kidney health and driving patient-centered technology solutions. "Mozarc Medical's focus will be on meaningful and innovative kidney health technologies that improve the overall patient experience and increase access to care globally," said Ven Manda, CEO of Mozarc Medical. "At a time when patient preferences are evolving and in-home kidney care is on the rise, Mozarc Medical is uniquely positioned to better serve patients with kidney disease around the world." Central…